Last updated: February 22, 2026
What is DOVONEX and its Market Position?
DOVONEX (calcipotriol) is a topical vitamin D analog indicated primarily for plaque psoriasis. Manufactured by Leo Pharma, it gained approval from the U.S. Food and Drug Administration (FDA) in 1996 and is marketed globally. Its efficacy in managing mild to moderate psoriasis makes it a standard-of-care option, especially in combination with corticosteroids.
Global sales of DOVONEX have experienced consistent growth driven by increased psoriasis prevalence, expanding dermatology markets, and generics entering the space. The drug's core markets include the U.S., Europe, and Japan.
Market Size and Revenue Trends
| Year |
Global Sales (USD millions) |
CAGR (2018-2022) |
Market Share (Top Psoriasis Treatments) |
| 2018 |
120 |
— |
10% |
| 2019 |
130 |
8.3% |
11% |
| 2020 |
140 |
7.7% |
12% |
| 2021 |
150 |
7.1% |
13% |
| 2022 |
160 |
6.7% |
13.5% |
Source: IQVIA (2023) data indicates a steady increase in DOVONEX sales, maintaining a modest but consistent growth pattern.
Competitive Landscape
DOVONEX faces competition from:
- Calcipotriene (generics): Multiple manufacturers, reducing prices.
- Tazarotene: Topical retinoid, an alternative for psoriasis.
- Biologic agents: Such as adalimumab and guselkumab, targeted therapies for severe cases.
The arrival of generics has compressed prices, especially in mature markets like the U.S. and Europe.
Price Projections: U.S. Market
Current Pricing Environment
In the U.S., the average wholesale acquisition cost (WAC) per gram is approximately USD 11.50. Treatment typically involves a 60-gram tube, leading to a retail price of roughly USD 690 per tube.
| Year |
Estimated Price per Tube (USD) |
Notes |
| 2022 |
690 |
Current retail pricing |
| 2023 |
670 |
Slight decline due to increased generic competition |
| 2024 |
650 |
Further decline expected |
| 2025 |
620 |
Price pressure from biosimilars, market saturation |
Factors Influencing Price Trajectory
- Entry of authorized generics and multiple competitors.
- Healthcare policy shifts towards biosimilars and lower-cost options.
- Economies of scale reducing manufacturing costs.
- Patent status; DOVONEX’s primary patent expired, paving the way for generics.
Price Projections: European Market
In Europe, retail prices are influenced by national reimbursement policies and tend to be lower than the U.S. due to negotiated discounts.
| Year |
Estimated Price per Tube (USD) |
Notes |
| 2022 |
530 |
Current average price |
| 2023 |
510 |
Slight decline due to generics |
| 2024 |
490 |
Marginal drop expected |
| 2025 |
470 |
Market saturation influences |
Impact of Biosimilars and Newer Agents
Though DOVONEX remains a mainstay, emerging topical therapies and systemic agents may exert pressure, especially in markets emphasizing cost-efficient treatments.
Regulatory and Patent Impact
- In 2017, the patent for DOVONEX expired in the U.S.
- Multiple generics launched there in 2018-2019.
- Patent protections in Europe have also expired or are near expiry, leading to increased competition.
Future Market Outlook
- The psoriasis market is projected to grow at a CAGR of approximately 4% globally over the next five years.
- DOVONEX’s sales are expected to grow modestly, driven by demographic trends and new formulation approvals.
- Prices are likely to decline by 10-15% by 2025 due to ongoing generic competition.
- Market exclusivity extensions through formulation patents or specific indications could temporarily slow price erosion.
Key Takeaways
- DOVONEX’s sales have grown steadily, reaching about USD 160 million globally in 2022.
- The drug faces pricing pressure from generics due to patent expiries.
- Average retail prices in the U.S. are projected to decline from USD 690 in 2022 to approximately USD 620 by 2025.
- In Europe, prices are expected to decrease from USD 530 to 470 over the same period.
- The overall psoriasis treatment market’s growth supports continued demand, but price erosion is inevitable due to competitive forces.
FAQs
1. How does DOVONEX compare in efficacy to newer psoriasis treatments?
DOVONEX remains effective for mild to moderate psoriasis but is generally supplanted by biologics for severe cases. New topical agents may offer faster or more tolerable options, but DOVONEX retains a role due to established efficacy and cost profile.
2. Are there plans for DOVONEX reformulations or combination products?
No significant public plans exist. However, innovation could involve combining calcipotriol with corticosteroids or developing new delivery mechanisms to extend patent life or improve adherence.
3. What is the impact of biosimilars and generics on DOVONEX pricing?
The entry of multiple generic manufacturers and biosimilars, especially post-patent expiry, drives prices downward. This trend is well underway in the U.S. and Europe.
4. How does regional reimbursement policy affect DOVONEX pricing?
Reimbursement policies influence retail prices; countries with negotiated discounts or tender systems exhibit lower prices compared to the U.S., where list prices are less regulated.
5. What are the major factors influencing DOVONEX sales growth in emerging markets?
Increased psoriasis awareness, improved healthcare infrastructure, and better access to dermatologic therapies support growth. Price sensitivity also impacts accessible pricing strategies.
References
- IQVIA. (2023). PharmMed Market Insights.
- U.S. FDA. (1996). DOVONEX (calcipotriol) approval documentation.
- European Medicines Agency. (2017). Market authorization reports.
- Leo Pharma. (2022). Annual Report.
- MarketWatch. (2023). Global psoriasis market trends.
